Exemestane
Exemestane is a third generation aromatase inhibitor that prevents estrogen synthesis and is clinically used to treat ER+ breast cancer. Exemestane exhibits anticancer chemotherapeutic activity, inhibiting proliferation and inducing cell cycle arrest, apoptosis, and autophagy in breast cancer cells.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18922787
| Cas No. |
107868-30-4 |
|---|---|
| Purity |
≥98% |
| Formula |
C20H24O2 |
| Formula Wt. |
296.40 |
| Chemical Name |
6-Methyleneandrosta-1,4-diene-3,17-dione |
| IUPAC Name |
(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione |
| Synonym |
Aromasin; FCE-24304 |
| Melting Point |
188-191°C |
| Solubility |
Soluble in methanol, ethanol (15 mg/mL), DMSO (54mg/mL) or dimethylformamide. Insoluble in water. |
| Appearance |
Yellowish to off white powder |
Amaral C, Borges M, Melo S, et al. Apoptosis and autophagy in breast cancer cells following exemestane treatment. PLoS One. 2012;7(8):e42398. PMID: 22912703.
Hong Y, Rashid R, Chen S. Binding features of steroidal and nonsteroidal inhibitors. Steroids. 2011 Jul;76(8):802-6. PMID: 21420422.
Bertelli G, Hall E, Ireland E, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)–a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Ann Oncol. 2010 Mar;21(3):498-505. PMID: 19717534.
